Israel's pharmaceutical giant, Teva will invest £12 million in clinical trials to take place in the UK, and has pledged a further £600,000 for dementia R&D.
The company says it will invest in a three-year dementia research programme, which with be facilitated by the National Institute of Health Research. The funding will also allow Teva access to the NIHR’s Biomedical Research Centres as well as the funder’s Translational Research Collaboration in Dementia.
The funding was announced on 12 March as part of a series of investments to the UK following a prime ministerial trade delegation to Israel last week.
This article on Research Professional News is only available to Research Professional or Pivot-RP users.
Research Professional users can log in and view the article via this link
Pivot-RP users can log in and view the article via this link.